The extended compliance period provides a 6-month window for a potential reverse stock split or capital raise to boost the bid price above $1.00. Monitor for any shareholder vote on reverse split or financing announcements. The stock remains at high risk of delisting if the company cannot execute a cure strategy by February 2027, which would severely reduce liquidity and institutional ownership.
Price Chart
Executive Summary
Mereo BioPharma received a second Nasdaq notice granting an additional 180-day compliance period (until February 16, 2027) to regain the $1.00 minimum bid price for its ADSs. The company failed to regain compliance during the initial 180-day period that expired August 17, 2026. Failure to cure by the new deadline will trigger delisting proceedings, though the company may appeal to a Nasdaq Hearings Panel. This filing extends the timeline but does not resolve the fundamental bid-price deficiency, keeping delisting risk alive for a micro-cap biotech with a $49M market cap and limited institutional ownership.
Key Facts
- Received second Nasdaq notice on August 18, 2026 for failure to maintain minimum $1.00 bid price per share
- Granted additional 180-day compliance period until February 16, 2027
- Initial 180-day compliance period expired August 17, 2026 without regaining compliance
- Must maintain closing bid price of at least $1.00 for 10 consecutive business days to regain compliance
- Failure to cure by February 16, 2027 will result in delisting, subject to appeal to Nasdaq Hearings Panel
- Market cap is $49M with only ~$3.8M in institutional holdings from top holders
Financial Impact
Delisting risk for a $49M market cap company; no specific financial figures provided in filing
Risk Factors
- Failure to regain compliance by February 16, 2027 will trigger Nasdaq delisting
- Micro-cap biotech with limited cash runway may struggle to execute a reverse split or raise capital
- Delisting would severely reduce institutional ownership and liquidity
- No specific plan or timeline disclosed for regaining compliance beyond monitoring bid price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-356168 |
| Document: 0001193125-26-356168-index-headers.html | 0001193125-26-356168 |
| Document: 0001193125-26-356168-index.html | 0001193125-26-356168 |
| Document: 0001193125-26-356168.txt | 0001193125-26-356168 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 19, 2026 9w ago | 8-K | $0.3115 $0.2780 | ▲ +10.75% | ▲ +10.37% | $0.2750 (+11.72%) |
Aug 11, 2026 10w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2750 (−10.13%) |
Aug 11, 2026 10w ago | Press Release | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2750 (−10.13%) |
Aug 11, 2026 10w ago | 8-K | $0.3060 $0.3130 | ▲ +2.29% | ▲ +2.69% | $0.2750 (−10.13%) |
Jun 11, 2026 19w ago | Institutional Cluster | $0.3118 $0.3100 | ▼ −0.58% | ▼ −1.01% | $0.2750 (−11.80%) |
May 12, 2026 23w ago | Press Release | $0.2460 $0.2370 | ▲ +3.66% | ▲ +3.74% | $0.2750 (−11.79%) |
Mar 19, 2026 31w ago | Press Release | $0.3610 $0.3390 | ▼ −6.09% | ▼ −3.88% | $0.2750 (−23.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers